​

Intellia Therapeutics (NTLA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NTLA Stock Forecast

Intellia Therapeutics (NTLA) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $26.29, with a high of $49.00 and a low of $13.00. This represents a 112.87% increase from the last price of $12.35.

$10 $18 $26 $34 $42 $50 High: $49 Avg: $26.29 Low: $13 Last Closed Price: $12.35

NTLA Stock Rating

Intellia Therapeutics stock's rating consensus is Buy, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 28 Buy (71.79%), 9 Hold (23.08%), 2 Sell (5.13%), and 0 Strong Sell (0.00%).

Buy
Total 39 0 2 9 28 Strong Sell Sell Hold Buy Strong Buy

NTLA Price Target Upside V Benchmarks

TypeNameUpside
StockIntellia Therapeutics112.87%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1623
Avg Price Target$17.00$26.50$21.39
Last Closing Price$12.35$12.35$12.35
Upside/Downside37.65%114.57%73.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2611191123
May, 2611291124
Apr, 2611391125
Mar, 26112101125
Feb, 2629111124
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 13, 2026Bernstein$17.00$13.9921.52%37.65%
May 12, 2026Canaccord Genuity$49.00$14.42239.81%296.76%
Apr 27, 2026Chardan Capital$30.00$13.03130.24%142.91%
Apr 27, 2026Leerink Partners$35.00$13.22164.75%183.40%
Apr 27, 2026Morgan Stanley$15.00$14.086.53%21.46%
Apr 27, 2026Jack AllenRobert W. Baird$13.00$13.94-6.74%5.26%
Jan 28, 2026KeyBanc$25.00$13.9579.21%102.43%
Jan 27, 2026Jack AllenRobert W. Baird$7.00$14.40-51.39%-43.32%
Nov 11, 2025Evercore ISI$8.00$9.73-17.78%-35.22%
Nov 10, 2025Truist Financial$14.00$9.9141.27%13.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 13, 2026BernsteinMarket PerformMarket Performhold
Apr 28, 2026Goldman SachsSellSellhold
Apr 28, 2026CitigroupOutperformOutperformhold
Mar 03, 2026Brookline CapitalBuyBuyhold
Mar 02, 2026Bank of America SecuritiesNeutralNeutralhold
Jan 28, 2026H.C. WainwrightBuyBuyhold
Jan 27, 2026CitigroupOutperformOutperformhold
Oct 30, 2025WedbushNeutralNeutralhold
Oct 28, 2025BarclaysOverweightOverweighthold
Oct 28, 2025CitigroupMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-25 $-14 $-3 $8 $19 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.78$-6.16$-5.42$-5.25$-3.81---
Avg Forecast$-3.60$-6.16$-5.44$-5.31$-5.13$-4.98$-2.60$1.51
High Forecast$-0.87$0.85$-4.98$-4.87$-4.04$-3.14$27.79$5.39
Low Forecast$-8.38$-21.52$-5.71$-5.63$-6.57$-7.02$-9.26$-0.20
Surprise %5.00%--0.37%-1.13%-25.73%---

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$33.05M$52.12M$36.27M$57.88M----
Avg Forecast$29.16M$51.90M$50.66M$53.93M$53.11M$39.23M$452.34M$1.25B
High Forecast$58.87M$151.42M$79.15M$63.58M$158.30M$116.94M$452.71M$3.71B
Low Forecast$12.12M$6.49M$37.80M$45.78M$6.78M$5.01M$451.97M$159.15M
Surprise %13.36%0.43%-28.39%7.32%----

Net Income Forecast

$-1B $-300M $400M $1B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-267.89M$-474.19M$-481.19M$-519.02M$-412.69M---
Avg Forecast$-230.77M$-354.34M$-481.19M$-466.19M$-527.95M$-559.65M$-271.07M$133.85M
High Forecast$-184.61M$-283.48M$-384.95M$-432.25M$-358.27M$-278.87M$2.47B$478.51M
Low Forecast$-276.92M$-425.21M$-577.43M$-500.12M$-583.20M$-622.89M$-821.94M$-17.93M
Surprise %16.09%33.82%-11.33%-21.83%---

NTLA Forecast FAQ

Is Intellia Therapeutics stock a buy?

Intellia Therapeutics stock has a consensus rating of Buy, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 28 Buy, 9 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Intellia Therapeutics is a favorable investment for most analysts.

What is Intellia Therapeutics's price target?

Intellia Therapeutics's price target, set by 39 Wall Street analysts, averages $26.29 over the next 12 months. The price target range spans from $13 at the low end to $49 at the high end, suggesting a potential 112.87% change from the previous closing price of $12.35.

How does Intellia Therapeutics stock forecast compare to its benchmarks?

Intellia Therapeutics's stock forecast shows a 112.87% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Intellia Therapeutics over the past three months?

  • June 2026: 4.35% Strong Buy, 47.83% Buy, 39.13% Hold, 4.35% Sell, 4.35% Strong Sell.
  • May 2026: 4.17% Strong Buy, 50.00% Buy, 37.50% Hold, 4.17% Sell, 4.17% Strong Sell.
  • April 2026: 4.00% Strong Buy, 52.00% Buy, 36.00% Hold, 4.00% Sell, 4.00% Strong Sell.

What is Intellia Therapeutics’s EPS forecast?

Intellia Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.98, marking a 30.71% increase from the reported $-3.81 in 2025. Estimates for the following years are $-2.6 in 2027, and $1.51 in 2028.

What is Intellia Therapeutics’s revenue forecast?

Intellia Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $39.23M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $452.34M, and $1.25B for 2028.

What is Intellia Therapeutics’s net income forecast?

Intellia Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-560M, representing an 35.61% increase from the reported $-413M in 2025. Projections indicate $-271M in 2027, and $133.85M in 2028.